IMIBIO-SL   20937
INSTITUTO MULTIDISCIPLINARIO DE INVESTIGACIONES BIOLOGICAS DE SAN LUIS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
PRENATAL TREATMENT WITH CAPTOPRIL INDUCES EMPHYSEMA IN RAT LUNG DEVELOPMENT
Autor/es:
CAPELARI, DN; SANCHEZ SI; FUENTES LB; ORTEGA HH; CIUFFO GM
Lugar:
San Juan
Reunión:
Congreso; Reunion Anual Soc. de Biologia de Cuyo; 2011
Institución organizadora:
Soc. de Biologia de Cuyo
Resumen:
Angiotensin-converting enzyme inhibitors (ACEI) have been widely used in hypertension treatment. However, the use of ACEI during pregnancy is contraindicated for risks of fetopathy. We investigated the effect of captopril prenatal treatment in lung development. Wistar rats were treated with captopril (2,85 mg/kg/day) delivered subcutaneously with osmotic mini-pumps during the last week of pregnancy. Pup‘s lungs at four different postnatal ages (P0, P8, P15 and P30) were evaluated by morphological, histomorphometric and immunohistochemistry staining analysis. Captopril treatment significantly decreased body and lung weights at P0 and P8. Histological study evidenced a substantial destruction of alveolar walls in treated rats, resulting in enlargement of distal airway spaces at P8, P15 and P30, demonstrated by significant increase in the interalveolar wall distance, quantified by mean linear intercept (MLI). Cellular proliferation was evaluated using PCNA (proliferating cell nuclear antigen). The percentage of PCNA-positively stained alveolar epithelial cells in the treated group was significantly higher at P15 and P30, respect to the control group. Cell proliferation decreased with age in control animals. However, in captopriltreated lungs the relative number of PCNA immunopositive nuclei remains high during the studied ages. These findings support the hypothesis of a functional renin-angiotensin-system required for normal lung development.